{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:08:51Z","timestamp":1790766531119,"version":"4.1.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"R1","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR40864"],"award-info":[{"award-number":["AR40864"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Muscular dystrophy (MD) is a group of progressive genetic diseases affecting the musculature that are characterized by inflammatory infiltrates, necrosis and connective tissue and fat replacement of the affected muscles. Unfortunately, treatments do not exist for the vast majority of MD patients. Adeno-associated viral vector (AAV)-based gene therapy is thus emerging as a potential treatment for many types of MD. Treatments strategies based on AAV are being adapted for replacement of mutant disease-causing genes, knockdown of dominant disease-causing genes using antisense oligonucleotides or inhibitory RNAs, delivery of gene editing tools such as clustered regularly interspaced short palindromic repeats\/Cas9 and effecting alterations in pre-mRNA splicing and by manipulating expression levels of modifier genes. Translational and clinical trial work focused on these types of AAV treatments for Duchenne MD, various limb girdle MDs, myotonic dystrophy 1, facioscapulohumeral MD, dysferlinopathies and congenital MDs are discussed here, with a focus on recent studies, pre-clinical large animal work and many promising ongoing and upcoming AAV clinical trials.<\/jats:p>","DOI":"10.1093\/hmg\/ddz128","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T15:10:22Z","timestamp":1559920222000},"page":"R102-R107","source":"Crossref","is-referenced-by-count":109,"title":["AAV-based gene therapies for the muscular dystrophies"],"prefix":"10.1093","volume":"28","author":[{"given":"Julie M","family":"Crudele","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Washington, Seattle, WA, USA"},{"name":"Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Washington, Seattle, WA, USA"},{"name":"Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"2019101710390288300_ref1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"2019101710390288300_ref2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"Lancet"},{"key":"2019101710390288300_ref3","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.cell.2015.05.026","article-title":"Dynamics of cell generation and turnover in the human heart","volume":"161","author":"Bergmann","year":"2015","journal-title":"Cell"},{"key":"2019101710390288300_ref4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/mus.24441","article-title":"Skeletal muscle satellite cells: mediators of muscle growth during development and implications for developmental disorders","volume":"50","author":"Dayanidhi","year":"2014","journal-title":"Muscle Nerve"},{"key":"2019101710390288300_ref5","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"2019101710390288300_ref6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"2019101710390288300_ref7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"2019101710390288300_ref8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of novel micro-dystrophins with enhanced functionality","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"2019101710390288300_ref9","doi-asserted-by":"crossref","first-page":"e1000958","DOI":"10.1371\/journal.pgen.1000958","article-title":"The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins","volume":"6","author":"Banks","year":"2010","journal-title":"PLoS Genet."},{"key":"2019101710390288300_ref10","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/hmg\/ddy197","article-title":"Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16\u201317","volume":"27","author":"Adams","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"2019101710390288300_ref11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI36612","article-title":"Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy","volume":"119","author":"Lai","year":"2009","journal-title":"J. Clin. Invest."},{"key":"2019101710390288300_ref12","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"issue":"5S1","key":"2019101710390288300_ref13","first-page":"193","article-title":"A blinded, placebo-controlled systemic gene therapy efficacy study in the GRMD model of Duchenne muscular dystrophy","volume":"25","author":"Birch","year":"2017","journal-title":"Mol. Ther."},{"issue":"5S1","key":"2019101710390288300_ref14","first-page":"5","article-title":"AAV micro-dystrophin therapy ameliorates muscular dystrophy in young adult Duchenne muscular dystrophy dogs for up to thirty months following injection","volume":"26","author":"Hakim","year":"2018","journal-title":"Mol. Ther."},{"key":"2019101710390288300_ref15","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","article-title":"Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus","volume":"24","author":"Yue","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"2019101710390288300_ref16","article-title":"Duchenne muscular dystrophy","author":"Genethon","year":"2019"},{"key":"2019101710390288300_ref17","volume-title":"Solid biosciences announces preliminary SGT-001 data and intention to dose escalate in IGNITE DMD clinical trial for duchenne muscular dystrophy","author":"Solid Biosciences","year":"2019"},{"key":"2019101710390288300_ref18","article-title":"Presented at the annual meeting of The American Society of Gene and Cell Therapy meeting","author":"Rodino-Klapac","year":"2019"},{"key":"2019101710390288300_ref19","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"2019101710390288300_ref20","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"2019101710390288300_ref21","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1073\/pnas.0604970103","article-title":"Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly (CUG) model for myotonic dystrophy","volume":"103","author":"Kanadia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019101710390288300_ref22","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/hmg\/ddz065","article-title":"MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity","volume":"28","author":"Yadava","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"2019101710390288300_ref23","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2019101710390288300_ref24","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF02388063","article-title":"Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle","volume":"25","author":"Clerk","year":"1993","journal-title":"Histochem. J."},{"key":"2019101710390288300_ref25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0960-8966(92)90004-P","article-title":"The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies","volume":"2","author":"Helliwell","year":"1992","journal-title":"Neuromuscul. Disord."},{"key":"2019101710390288300_ref26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/mt.2008.149","article-title":"Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/utrophin-deficient mice","volume":"16","author":"Odom","year":"2008","journal-title":"Mol. Ther."},{"key":"2019101710390288300_ref27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2018.10.005","article-title":"Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2\/mdx mice","volume":"11","author":"Kennedy","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710390288300_ref28","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1073\/pnas.082613599","article-title":"Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice","volume":"99","author":"Nguyen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019101710390288300_ref29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","article-title":"rAAVrh74.MCK.GALGT2 protects against loss of hemodynamic function in the aging mdx mouse heart","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"2019101710390288300_ref30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nmd.2006.12.004","article-title":"Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism","volume":"17","author":"Xu","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"2019101710390288300_ref31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2353\/ajpath.2007.060927","article-title":"Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A","volume":"171","author":"Xu","year":"2007","journal-title":"Am. J. Pathol."},{"key":"2019101710390288300_ref32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2353\/ajpath.2009.080967","article-title":"Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice","volume":"175","author":"Xu","year":"2009","journal-title":"Am. J. Pathol."},{"key":"2019101710390288300_ref33","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/j.ajpath.2016.05.021","article-title":"B4GALNT2 (GALGT2) gene therapy reduces skeletal muscle pathology in the FKRP P448L mouse model of limb girdle muscular dystrophy 2I","volume":"186","author":"Thomas","year":"2016","journal-title":"Am. J. Pathol."},{"key":"2019101710390288300_ref34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/dbio.2001.0530","article-title":"Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression","volume":"242","author":"Xia","year":"2002","journal-title":"Dev. Biol."},{"key":"2019101710390288300_ref35","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1021\/pr300328r","article-title":"Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle","volume":"11","author":"Yoon","year":"2012","journal-title":"J. Proteome Res."},{"key":"2019101710390288300_ref36","doi-asserted-by":"crossref","first-page":"13915","DOI":"10.1073\/pnas.0905780106","article-title":"Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy","volume":"106","author":"Mulders","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019101710390288300_ref37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature11362","article-title":"Targeting nuclear RNA for in vivo correction of myotonic dystrophy","volume":"488","author":"Wheeler","year":"2012","journal-title":"Nature"},{"key":"2019101710390288300_ref38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.gt.3301955","article-title":"Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions","volume":"10","author":"Furling","year":"2003","journal-title":"Gene Ther."},{"key":"2019101710390288300_ref39","article-title":"Letter from Ionis Pharmaceuticals & Biogen to the MDF Community, Myotonic Dystrophy Foundation","author":"Ionis Pharmaceuticals and Biogen","year":"2017"},{"key":"2019101710390288300_ref40","article-title":"Audentes is developing AT466 for the treatment of myotonic dystrophy type 1","author":"Audentes Therapeutics"},{"key":"2019101710390288300_ref41","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1093\/hmg\/ddv219","article-title":"Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy","volume":"24","author":"Bisset","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"2019101710390288300_ref42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/cphy.c160039","article-title":"Facioscapulohumeral muscular dystrophy","volume":"7","author":"DeSimone","year":"2017","journal-title":"Compr. Physiol."},{"key":"2019101710390288300_ref43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","article-title":"Pre-clinical safety and off-target studies to support translation of AAV-mediated RNAi therapy for FSHD","volume":"8","author":"Wallace","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710390288300_ref44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"issue":"4S1","key":"2019101710390288300_ref45","first-page":"22","article-title":"correction of dystrophin expression in old dystrophic dogs","volume":"27","author":"Bengtsson","year":"2019","journal-title":"Mol. Ther."},{"key":"2019101710390288300_ref46","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat. Commun."},{"key":"2019101710390288300_ref47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nbt.4148","article-title":"Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy","volume":"36","author":"Ryu","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"2019101710390288300_ref48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"2019101710390288300_ref49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-017-00924-7","article-title":"Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle","volume":"8","author":"Novak","year":"2017","journal-title":"Nat. Commun."},{"key":"2019101710390288300_ref50","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/hmg\/dds082","article-title":"Rescue of severely affected dystrophin\/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping","volume":"21","author":"Goyenvalle","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"2019101710390288300_ref51","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1038\/mt.2012.181","article-title":"Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping","volume":"20","author":"Vulin","year":"2012","journal-title":"Mol. Ther."},{"key":"2019101710390288300_ref52","article-title":"Audentes Therapeutics announces expansion of AAV technology platform and pipeline with new development programs for Duchenne muscular dystrophy and myotonic dystrophy","author":"Therapeutics","year":"2019"},{"key":"2019101710390288300_ref53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/JND-150109","article-title":"Exon 32 skipping of dysferlin rescues membrane repair in patients\u2019 cells","volume":"2","author":"Barthelemy","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"2019101710390288300_ref54","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","article-title":"Identification of novel antisense-mediated exon skipping targets in DYSF for therapeutic treatment of dysferlinopathy","volume":"13","author":"Lee","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2019101710390288300_ref55","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1017\/S1462399409001203","article-title":"Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects","volume":"11","author":"Sandona","year":"2009","journal-title":"Expert Rev. Mol. Med."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddz128\/29113474\/ddz128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R102\/30160325\/ddz128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R102\/30160325\/ddz128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T10:39:33Z","timestamp":1571308773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/28\/R1\/R102\/5522633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":55,"journal-issue":{"issue":"R1","published-online":{"date-parts":[[2019,6,25]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddz128","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,6,25]]}}}